Allergy Therapeutics Plc is a specialty pharmaceutical company focused on developing innovative therapies to treat and prevent allergic diseases. It works on next-generation allergy vaccines featuring novel adjuvants, improved dosing regimens, and new delivery formats. Its marketed/registered products include Grass MATA (Modified Allergen Tyrosine Adsorbed), Tree MATA, Ragweed MATA, Bee Venom SCIT (subcutaneous immunotherapy), and Wasp Venom SCIT, among others. The company also offers a broad portfolio of allergen extracts for skin prick testing and a wide range of well-characterized diagnostic products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Allergy Therapeutics' research and development (R&D) activities focus on developing new therapies for allergy treatment and allergy prevention. The company has been involved in pivotal clinical trials, such as the Phase III G306 trial and the ongoing Phase III G308 trial, which are crucial for developing new treatment approaches for allergies. The company’s product pipeline in clinical development includes vaccines for tree, grass and house dust mite, and a peanut allergy vaccine in pre-clinical development. It is developing Grass MATA MPL, Birch MATA MPL and Ragweed MATA MPL in Phase III trials; Trees MATA MPL in Phase II trials; VLP Peanut in Phase I trials; and VLP vaccines outside allergy in pre-clinical trials. In FY2025, the company spent GBP15.3 million on its R&D activities, which as a percentage of revenue stood at 27.9%, and decreased 32.8% YoY.